Skip to main content

Table 3 Incidence of clinically relevant toxicities

From: Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

Toxicities Cohort 1   Cohort 2   Cohort 3   Cohort 4   Cohort 5   Cohort 6  
  Toxicity Grade
  1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
Alkaline phosphatase elevation 0 0 0 0 0 0 0 1 0 0 0 0
Anemia 0 0 1 0 0 0 0 0 0 0 0 0
Creatinine elevation 1 0 2 0 0 0 0 0 0 0 0 0
Edema 0 0 0 0 0 0 0 0 0 0 1 0
Hyperkalemia 1 0 0 0 0 0 0 0 0 0 0 0
Hypoalbuminemia 0 0 1 0 0 0 0 0 0 0 0 0
Infection 0 0 0 1* 0 0 0 0 0 0 0 0
Insomnia 0 0 0 0 1 0 0 0 0 0 0 0
Nausea/emesis 0 0 0 0 1 0 0 0 0 0 0 1
Neuropathy 0 0 1 0 0 0 1 0 0 0 0 0
Pruritis 0 0 1 0 0 0 0 0 0 0 0 0
Weakness/fatigue 0 0 1 1 0 0 0 0 0 0 0 0
  1. * Right gluteal and inguinal furuncles (culture positive for mixed flora – gram positive and gram cocci as well as methicillin sensitive and resistant staph aureus.